Contra-indicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome Type 2.
- TRADE NAME: Trulicity (Lilly)
- INDICATIONS: To improve glycemic control in adults with Type II diabetes mellitus
- CLASS: Antidiabetic, Glucagon-like peptide-1 (GLP-1) receptor agonist
- HALF-LIFE: 5 days
- FDA APPROVAL DATE: 09/18/2014
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 04/24/2025
